Tucatinib(CAS: 937263-43-9)

Tucatinib (CAS: 937263-43-9) is regulated under the Globally Harmonized System of Classification and Labelling of Chemicals (GHS), and falls under the purview of the European Union’s Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) regulation. Additionally, FDA and EPA have specific requirements for its handling, storage, and disposal, ensuring safety and environmental protection.

Alternatives to tucatinib (CAS: 937263-43-9) in synthesis include similar drug candidates with similar mechanisms of action, such as pertuzumab and trastuzumab, which are often used as alternatives. Common substitutes in the synthesis process include alternative reagents like oxalyl chloride or thionyl chloride, depending on the specific synthetic route.

The market for tucatinib (CAS: 937263-43-9) is growing, driven by increasing research interest in HER2-positive breast cancer treatments. Market trends show a focus on personalized medicine and combination therapies. Research is also exploring the potential of tucatinib in combination with other drugs to improve efficacy and expand its application in oncology.

Waste containing tucatinib (CAS: 937263-43-9) should be collected in appropriate containers, labeled with the chemical name and CAS number. Incineration or professional waste disposal services should be used for disposal. Environmental protection precautions include ensuring no spillage or leaks occur, and following local and national environmental regulations to prevent contamination of soil and water sources.